Truist Financial Maintains Mersana Therapeutics(MRSN.US) With Buy Rating

Moomoo News53minutes ago · Ratings

Express News | Mersana Therapeutics Inc : Guggenheim Cuts Target Price to $5 From $7

Reuters06:36 ET

Mersana Therapeutics Selloff on Data Overdone, Says BTIG

TipRanksJan 11 14:45 ET

Buy Rating for Mersana Therapeutics: Promising Efficacy and Safety of Emi-Le ADC Amid Stock Price Volatility

TipRanksJan 11 10:26 ET · Ratings

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaJan 10 16:06 ET

Wedbush Cuts Price Target on Mersana Therapeutics to $4 From $7, Keeps Outperform Rating

MT NewswiresJan 10 13:01 ET · Ratings